Rhythm Pharma's Drug for Rare Obesity Meets Late-stage Trial Goal

This post was originally published on Medscape

You will shortly be re-directed to the publisher's website

Rhythm Pharmaceuticals said on Monday its drug Imcivree notably reduced weight in patients with a rare obesity disorder caused by damage to the brain, meeting the main goal…
Reuters Health Information